Staphylococcus aureus sepsis after etanercept induction in a hemodialysis patient.
Summary of "Staphylococcus aureus sepsis after etanercept induction in a hemodialysis patient."
No Summary Available
Affiliation
Department of Internal Medicine, Nihon University Nerima-Hikarigaoka Hospital, 2-11-1 Hikarigaoka, Nerima, Tokyo, Japan; Division of Hematology and Rheumatology, Itabashi, Tokyo, Japan.
Journal Details
This article was published in the following journal.
Name: Hemodialysis international. International Symposium on Home Hemodialysis
ISSN: 1542-4758
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22742581
- DOI: http://dx.doi.org/10.1111/j.1542-4758.2012.00723.x
Medical and Biotech [MESH] Definitions
Methicillin-resistant Staphylococcus Aureus
A strain of Staphylococcus aureus that is non-susceptible to the action of METHICILLIN. The mechanism of resistance usually involves modification of normal or the presence of acquired PENICILLIN BINDING PROTEINS.
Lysostaphin
A 25-kDa peptidase produced by Staphylococcus simulans which cleaves a glycine-glcyine bond unique to an inter-peptide cross-bridge of the STAPHYLOCOCCUS AUREUS cell wall. EC 3.4.24.75.
Pneumonia, Staphylococcal
Pneumonia caused by infections with bacteria of the genus STAPHYLOCOCCUS, usually with STAPHYLOCOCCUS AUREUS.
Hemodialysis Units, Hospital
Hospital units in which care is provided the hemodialysis patient. This includes hemodialysis centers in hospitals.
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
PubMed Articles
Abstract Background: In this study, we aimed to determine the nasal carriage rate of Staphylococcus aureus and risk factors in hemodialysis (HD) patients. Methods: One hundred eighty-four HD patients...
The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients.
Staphylococcus aureus infections are a substantial problem for hemodialysis patients. Several vaccine candidates are currently under development, with hemodialysis patients being one possible target p...
Exploring Staphylococcus aureus pathways to disease for vaccine development.
Staphylococcus aureus is a commensal of the human skin or nares and a pathogen that frequently causes skin and soft tissue infections as well as bacteremia and sepsis. Recent efforts in understanding...
Objective: The purpose of this study was to determine the nasal carriage rate of Staphylococcus aureus in hemodialysis patients and the antibiogram of all isolated S. aureus from carriers. Subjects an...
Septic arthritis as an initial manifestation of a bacterial endocarditis.
Septic arthritis due to endocarditis is a rare and life-threatening disease. Endocarditis occurs with an incidence of 30 patients per 1 million citizens/year. Staphylococcus aureus is one of the most...
Clinical Trials
Evaluation of a Diagnostic Device for Detection of Nasal Staphylococcus Aureus
To establish the clinical test performance characteristics of sensitivity, specificity and predictive values for direct detection of nasal Staphylococcus aureus colonization against clinic...
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
Two part study testing the effectiveness and safety of StaphVAX vaccine in chronic hemodialysis patients against infection by Staphylococcus aureus.
Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia
To study whether fluoroquinolone (trovafloxacin or levofloxacin), added to standard treatment, could reduce the high mortality and complication rates in Staphylococcus aureus bacteremia.
Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus
Primary Objective: 1. Evaluate the efficacy and safety of daptomycin given for treatment of catheter-related bloodstream infections due to S. aureus bacteria with or without exchange of t...
Hospitalized patients at least 18 years of age, with Staphylococcus aureus bacteremia (SAB) will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1,...
